Coric V - Search Results

Year	Number of Results
1993	2
1996	2
1997	1
1998	1
1999	1
2002	2
2003	1
2004	1
2005	13
2006	20
2007	6
2008	5
2009	4
2010	4
2011	1
2012	4
2013	10
2014	6
2015	6
2016	8
2017	6
2018	5
2019	9
2020	7
2021	11
2022	21
2023	14
2024	4

1

Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial.

Lipton RB, Croop R, Stock DA, Madonia J, Forshaw M, Lovegren M, Mosher L, Coric V, Goadsby PJ. Lipton RB, et al. Among authors: coric v. Lancet Neurol. 2023 Mar;22(3):209-217. doi: 10.1016/S1474-4422(22)00517-8. Lancet Neurol. 2023. PMID: 36804093 Clinical Trial.

2

Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.

Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, Stock EG, Coric V, Goadsby PJ. Croop R, et al. Among authors: coric v. Lancet. 2021 Jan 2;397(10268):51-60. doi: 10.1016/S0140-6736(20)32544-7. Epub 2020 Dec 15. Lancet. 2021. PMID: 33338437 Clinical Trial.

3

Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial.

Croop R, Madonia J, Stock DA, Thiry A, Forshaw M, Murphy A, Coric V, Lipton RB. Croop R, et al. Among authors: coric v. Headache. 2022 Oct;62(9):1153-1163. doi: 10.1111/head.14389. Epub 2022 Oct 14. Headache. 2022. PMID: 36239038 Free PMC article. Clinical Trial.

4

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.

Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB. Croop R, et al. Among authors: coric v. Lancet. 2019 Aug 31;394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X. Epub 2019 Jul 13. Lancet. 2019. PMID: 31311674 Clinical Trial.

5

Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.

Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ. Lipton RB, et al. Among authors: coric v. N Engl J Med. 2019 Jul 11;381(2):142-149. doi: 10.1056/NEJMoa1811090. N Engl J Med. 2019. PMID: 31291516 Clinical Trial.

6

Revealing the complex genetic architecture of obsessive-compulsive disorder using meta-analysis.

International Obsessive Compulsive Disorder Foundation Genetics Collaborative (IOCDF-GC) and OCD Collaborative Genetics Association Studies (OCGAS). International Obsessive Compulsive Disorder Foundation Genetics Collaborative (IOCDF-GC) and OCD Collaborative Genetics Association Studies (OCGAS). Mol Psychiatry. 2018 May;23(5):1181-1188. doi: 10.1038/mp.2017.154. Epub 2017 Aug 1. Mol Psychiatry. 2018. PMID: 28761083 Free PMC article.

7

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.

Berman G, Croop R, Kudrow D, Halverson P, Lovegren M, Thiry AC, Conway CM, Coric V, Lipton RB. Berman G, et al. Among authors: coric v. Headache. 2020 Sep;60(8):1734-1742. doi: 10.1111/head.13930. Epub 2020 Aug 16. Headache. 2020. PMID: 32799325 Free PMC article. Clinical Trial.

8

Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000-201).

Johnston K, Harris L, Powell L, Popoff E, Coric V, L'Italien G, Schreiber CP. Johnston K, et al. Among authors: coric v. J Headache Pain. 2022 Jan 17;23(1):10. doi: 10.1186/s10194-021-01378-5. J Headache Pain. 2022. PMID: 35038983 Free PMC article. Clinical Trial.

9

Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials.

Lipton RB, Blumenfeld A, Jensen CM, Croop R, Thiry A, L'Italien G, Morris BA, Coric V, Goadsby PJ. Lipton RB, et al. Among authors: coric v. Cephalalgia. 2023 Feb;43(2):3331024221141686. doi: 10.1177/03331024221141686. Cephalalgia. 2023. PMID: 36739511 Free article.

10

Treatment options in stage I seminoma.

Bumbasirevic U, Zivkovic M, Petrovic M, Coric V, Lisicic N, Bojanic N. Bumbasirevic U, et al. Among authors: coric v. Oncol Res. 2023 Jan 12;30(3):117-128. doi: 10.32604/or.2022.027511. eCollection 2022. Oncol Res. 2023. PMID: 37305015 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

155 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Results by year